em 523 has been researched along with tris(2,2'-bipyridine)ruthenium iii in 1 studies
| Studies (em 523) | Trials (em 523) | Recent Studies (post-2010) (em 523) | Studies (tris(2,2'-bipyridine)ruthenium iii) | Trials (tris(2,2'-bipyridine)ruthenium iii) | Recent Studies (post-2010) (tris(2,2'-bipyridine)ruthenium iii) |
|---|---|---|---|---|---|
| 26 | 1 | 0 | 37 | 0 | 11 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, I; Monji, H; Ueno, H; Yamaguchi, M | 1 |
1 other study(ies) available for em 523 and tris(2,2'-bipyridine)ruthenium iii
| Article | Year |
|---|---|
Highly sensitive high-performance liquid chromatographic determination method for a new erythromycin derivative, EM523, and its major metabolites in human plasma and urine using post-column tris(2,2'-bipyridine) ruthenium(III) chemiluminescence detection.
Topics: 2,2'-Dipyridyl; Chromatography, High Pressure Liquid; Erythromycin; Gastrointestinal Agents; Humans; Luminescent Measurements; Organometallic Compounds; Sensitivity and Specificity | 1997 |